# Weekly Research and Decision Review — 2026-07-26
DRAFT for human review. Not financial advice.

## Run metadata
- Model / research mode: GPT-5.6 Thinking / continuity-first, evidence-gated hybrid
- Input snapshot / SHA-256: `data/research_snapshot.csv` / `564467de230c68e0f3429fa65168d4b551a892a28f1b2f963063c07841a81334`
- Snapshot generated: 2026-07-24 20:38:43 UTC; 0 rows
- Prior reports reviewed: `research/candidates-2026-07-19.md` and matching manifest
- Active recommendations reviewed: 0 (`data/recommendations.csv` contains only its header)
- Open positions reviewed: 1 (`CELC`, trade `2026-0004`)
- New leads / Actionable / Early Watch / Reject: 0 / 0 / 0 / 1
- Weekly decision: **NO NEW TRADE**

## Prior recommendation audit

No durable recommendation objects are currently recorded in `data/recommendations.csv`. The prior run produced no Actionable or Early Watch recommendation, so there is no recommendation ID to carry, upgrade, or remove.

## Existing positions

### CELC — MANAGE
- Linked trade: `2026-0004`, recorded open since 2026-06-23 at 89.86 with original stop/invalidation 85.37.
- Original thesis / current thesis: the recorded thesis was the FDA decision for gedatolisib. Celcuity announced FDA approval of REVTORPYK on 2026-07-14, three days before the recorded 2026-07-17 PDUFA goal date. The original binary-event thesis is complete.
- Current primary-source context: Celcuity says commercial launch is anticipated in late Q3 2026 and an sNDA submission is planned in Q3 2026, but neither statement supplies an exact binding date inside the current Actionable or Early Watch horizons. Celcuity IR currently lists no upcoming event.
- Financing / dilution context: the prior report identified the June 2026 upsized convertible-note financing. Commercial launch execution, cash use, financing effects, adoption and post-approval volatility now dominate the risk profile.
- Original invalidation: preserve 85.37 for audit purposes. This research review does not infer that the broker position, stop or size changed.
- Structured-data limitation: CELC is absent because the canonical snapshot contains zero rows. No current structure-based management level, setup or planned R can be evidenced from the committed data pack.
- This week's management review: reconcile the journal's still-open status with the broker. Decide explicitly whether a post-approval commercialization thesis exists. Do not add merely because approval occurred; any new setup requires a fresh structured market-data row, defensible levels and a separate recommendation/proposal.
- Next review: 2026-08-02, or immediately after explicit broker-status confirmation or a new dated primary-source event.

## Coming-week decision sheet

**NO NEW TRADE.** The canonical snapshot contains no current rows, there are no active recommendation objects, and no new candidate can satisfy the required structured-market-data and setup gates.

### CELC — MANAGE
- Continuity: open trade `2026-0004`; no durable recommendation ID exists.
- What changed: no new primary-source event after the July 14 approval was found. The issuer currently lists no upcoming event, while late-Q3 launch and Q3 sNDA plans remain broad windows rather than exact dates.
- Why this action: management review is required because the original catalyst is complete, but the repository still records the trade as open. No add-on or new-entry inference is permitted.
- Promotion condition: none for the current completed thesis. A new recommendation requires current structured market data, an allowed setup and a separately verified future catalyst or intermediate trigger.
- Removal condition: broker reconciliation confirms the position is closed, or the human explicitly archives the completed thesis.
- Next review date: 2026-08-02.

## New research

No new research candidate survived discovery. `data/research_snapshot.csv` has zero rows, so scanner and canonical market-data breadth are absent. Public calendars and search leads were not promoted because a third-party lead cannot replace the required primary date and structured market-data evidence.

## European preliminary sourcing

The required four-name XETRA preliminary pass could not be completed from the canonical data pack because the snapshot contains no rows and no relevant recent EU scan object was available in the loaded repository inputs. Padding with stale prior names would violate the discovery and verification rules.

## Removed or expired

- CELC new-entry FDA-decision thesis — expired/completed when approval was announced on 2026-07-14.
- No new candidates were added to or removed from the durable recommendation registry.

## Sources used

- Repository instructions and research-method files on `main`.
- Canonical structured input: `data/research_snapshot.csv`, generated 2026-07-24; SHA-256 `564467de230c68e0f3429fa65168d4b551a892a28f1b2f963063c07841a81334`.
- Repository continuity: `trades.csv`, `data/recommendations.csv`, `research/candidates-2026-07-19.md` and matching manifest.
- Celcuity primary approval source: https://ir.celcuity.com/news-releases/news-release-details/celcuity-announces-fda-approval-revtorpyktm-gedatolisib
- Celcuity investor-relations page: https://ir.celcuity.com/
